Published • loading... • Updated
Novo Nordisk Wins China Patent Extension for Ozempic Kidney Disease Use
Summary by chinamoneynetwork.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Novo Nordisk Wins China Patent Extension for Ozempic Kidney Disease Use
Novo Nordisk said China has approved a five-year patent term extension tied to the chronic kidney disease indication for Ozempic, the company's semaglutide injection, extending related patent protection to March 2031. The decision by the China National Intellectual Property Administration gives the drugmaker additional intellectual property protection for one of the product's newer uses in a market with a large diabetes burden. The approval stre…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
